Literature DB >> 3123281

Successful use of gonadotropin-releasing hormone agonist leuprolide for in vitro fertilization in a patient with polycystic ovarian disease and infertility unresponsive to standard treatment.

E Radwanska1, R G Rawlins, I Tummon, V Maclin, Z Binor, W P Dmowski.   

Abstract

A patient with PCO and primary infertility had undergone numerous failed attempts of ovulation induction. She then was treated with GnRHa leuprolide 500 micrograms subcutaneously daily for 4 weeks, later combined with hMG 225 IU IM daily for 8 days and hCG 5000 IU IM. Six oocytes were retrieved for IVF, four fertilized and two were replaced. Twin pregnancy was established and delivered at term. Hyperstimulation syndrome was managed conservatively.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3123281     DOI: 10.1016/s0015-0282(16)59728-3

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  4 in total

1.  Ovarian hyperstimulation associated with the sole use of leuprolide for ovarian suppression.

Authors:  J Yeh; R L Barbieri; V A Ravnikar
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-08

Review 2.  Polycystic ovarian disease (PCOD)--pregnancy rate and outcome in in vitro fertilization.

Authors:  D Bider; D Levran; S Mashiach; I Ben-Shlomo; J Dor
Journal:  J Assist Reprod Genet       Date:  1993-01       Impact factor: 3.412

3.  Effectiveness of short pituitary suppression with gonadotropin-releasing hormone agonist leuprolide during induction of ovulation for in vitro fertilization.

Authors:  I Henig; P J Chan; S G Prough; D R Tredway
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-08

4.  The effect of leuprolide acetate on steroidogenesis by granulosa and theca cells in vitro.

Authors:  J L Frederick; M J Hickey; M M Francis; M V Sauer; R J Paulson
Journal:  J In Vitro Fert Embryo Transf       Date:  1991-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.